Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 10Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Healthy Participants 2Uterine Cervical Neoplasms 1Solid Tumour 1Recurrence 1Ovarian Neoplasms 1Moderate Hepatic Impairment 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1Endometrial Neoplasms 1Disease Progression 1Advanced Solid Tumours 1Advanced Solid Malignancy, 1Advanced Solid Malignancy 1

Interventions

capivasertib 2Fulvestrant 2ribociclib 1palbociclib 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Locally Advanced (Inoperable) or Metastatic Breast Cancer × capivasertib × Clear all
NCT04862663 2026-05-27

CAPItello-292

AstraZeneca

Phase 3 Recruiting
895 enrolled
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT04305496 2026-04-30

CAPItello-291

AstraZeneca

Phase 3 Active not recruiting
818 enrolled 19 charts 2 FDA
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡